Mon panier

HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL)

HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL) Liste de produits

  • Attribut

    Protein (2)

  • Bibliothèque de produits

    En ligne (2)

  • Espèces

    Human (2)

  • Étiquette

    His Tag & Avi Tag (1)His Tag (1)

  • Marqueur

    Biotin-labeled (1)PE Labeled (1)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
HLP-H82Ec
Human
HEK293
Biotinylated Human HLA-A*02:01&B2M&EBV LMP1 (YLLEMLWRL) Complex Protein (Monomer, MALS verified) Ajouter au panier
HLP-HP2Hd
Human
HEK293
PE-Labeled Human HLA-A*02:01&B2M&EBV LMP1 (YLLEMLWRL) Tetramer Protein Ajouter au panier
Quantité totale2
  • 1

HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL)Contexte de la molécule

Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. The Human HLA-A*0201 EBV LMP1 (YLLEMLWRL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLLEMLWRL peptide of the EBV LMP1.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
NGM-313NGM-313; MK-3655Phase 2 ClinicalNgm Biopharmaceuticals IncMetabolic Dysfunction-Associated Steatotic Liver Disease; Hepatitis; Obesity
Details
FazpilodemabRG-7992; BFKB-8488A; RO-7040551Phase 1 ClinicalGenentech IncMetabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Insulin Resistance
Details
B-1344B-1344Phase 1 ClinicalTasly Biomedical Co LtdMetabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2
Details
  • Liste de produits
  • Informations sur les médicaments cliniques